Literature DB >> 35411471

Impact of antithrombotic agents on short-term outcomes following minimally invasive colorectal cancer surgery: a propensity score-matched analysis.

Toshinori Sueda1, Mitsuyoshi Tei2, Kentaro Nishida2, Masatoshi Nomura2, Yukihiro Yoshikawa2, Tae Matsumura2, Chikato Koga2, Hiromichi Miyagaki2, Masanori Tsujie2, Yusuke Akamaru2.   

Abstract

BACKGROUND: It remains unclear whether minimally invasive colorectal cancer (CRC) surgery under the suitable management of perioperative antithrombotic therapy (ATT) is safe and feasible in patients treated with chronic ATT. The present study aimed to assess the impact of ATT on short-term outcomes following minimally invasive CRC surgery.
METHODS: We retrospectively analyzed 1495 consecutive patients who underwent elective minimally invasive CRC surgery between 2011 and 2021, using propensity score-matched analysis.
RESULTS: Overall, 230 patients had chronically received ATT. After propensity score matching, we enrolled 412 patients (n = 206 in each group). Before matching, significant group-dependent differences were observed in terms of sex (p < 0.01), age (p < 0.01), American Society of Anesthesiologists' physical status (p < 0.01), body mass index (p < 0.01), and pathological N classification (p = 0.03). The frequencies of overall postoperative complications, bleeding events, and thromboembolic events were significantly higher in the ATT group than in the Non-ATT group (p < 0.01). After matching, no significant differences were found between the groups in terms of clinical or surgical characteristics, or in terms of the frequency of overall postoperative complications, bleeding events, thromboembolic events, length of postoperative stay, or any other postoperative complication. Multivariate analysis identified no significant risk factors for postoperative bleeding events or severe postoperative complications associated with ATT.
CONCLUSIONS: Patients treated with chronic ATT showed acceptable short-term outcomes for minimally invasive CRC surgery compared with those not receiving ATT. Minimally invasive CRC surgery appears safe and feasible under the suitable management of perioperative ATT regardless of whether the patient has a history of ATT.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Antithrombotic therapy; Bleeding complications; Colorectal cancer; Propensity score matching; Short-term outcomes

Mesh:

Substances:

Year:  2022        PMID: 35411471     DOI: 10.1007/s00384-022-04148-0

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  17 in total

Review 1.  Perioperative risk assessment in elderly and high-risk patients.

Authors:  J David Richardson; Christine S Cocanour; John A Kern; R Neal Garrison; Orlando C Kirton; Joseph B Cofer; David A Spain; Michael H Thomason
Journal:  J Am Coll Surg       Date:  2004-07       Impact factor: 6.113

2.  Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  James D Douketis; Alex C Spyropoulos; Frederick A Spencer; Michael Mayr; Amir K Jaffer; Mark H Eckman; Andrew S Dunn; Regina Kunz
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Laparoscopic versus open surgery for rectal cancer: long-term oncologic results.

Authors:  Christophe Laurent; Fabien Leblanc; Philippe Wütrich; Mathieu Scheffler; Eric Rullier
Journal:  Ann Surg       Date:  2009-07       Impact factor: 12.969

Review 4.  Gastrointestinal surgery in old age: issues of equality and quality.

Authors:  D G Seymour
Journal:  Gut       Date:  1997-10       Impact factor: 23.059

5.  Relative importance of preoperative health status versus intraoperative factors in predicting postoperative adverse outcomes in geriatric surgical patients.

Authors:  J M Leung; S Dzankic
Journal:  J Am Geriatr Soc       Date:  2001-08       Impact factor: 5.562

6.  Laparoscopic colon and rectal surgery at a VA hospital. Analysis of the first 50 cases.

Authors:  D G Begos; J Arsenault; G H Ballantyne
Journal:  Surg Endosc       Date:  1996-11       Impact factor: 4.584

Review 7.  Management of surgical patients receiving anticoagulation and antiplatelet agents.

Authors:  J Thachil; A Gatt; V Martlew
Journal:  Br J Surg       Date:  2008-12       Impact factor: 6.939

8.  Optimal use of antiplatelet agents, especially aspirin, in the perioperative management of colorectal cancer patients undergoing laparoscopic colorectal resection.

Authors:  Yasunori Yoshimoto; Takahisa Fujikawa; Akira Tanaka; Hideto Hayashi; Norihiro Shimoike; Hiroshi Kawamoto; Chiyo Nakasuga; Tsunenori Yamamoto
Journal:  World J Surg Oncol       Date:  2019-06-01       Impact factor: 2.754

9.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer.

Authors:  Yojiro Hashiguchi; Kei Muro; Yutaka Saito; Yoshinori Ito; Yoichi Ajioka; Tetsuya Hamaguchi; Kiyoshi Hasegawa; Kinichi Hotta; Hideyuki Ishida; Megumi Ishiguro; Soichiro Ishihara; Yukihide Kanemitsu; Yusuke Kinugasa; Keiko Murofushi; Takako Eguchi Nakajima; Shiro Oka; Toshiaki Tanaka; Hiroya Taniguchi; Akihito Tsuji; Keisuke Uehara; Hideki Ueno; Takeharu Yamanaka; Kentaro Yamazaki; Masahiro Yoshida; Takayuki Yoshino; Michio Itabashi; Kentaro Sakamaki; Keiji Sano; Yasuhiro Shimada; Shinji Tanaka; Hiroyuki Uetake; Shigeki Yamaguchi; Naohiko Yamaguchi; Hirotoshi Kobayashi; Keiji Matsuda; Kenjiro Kotake; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2019-06-15       Impact factor: 3.402

10.  Surgical outcomes for colon and rectal cancer over a decade: results from a consecutive monocentric experience in 902 unselected patients.

Authors:  Bruno Andreoni; Antonio Chiappa; Emilio Bertani; Massimo Bellomi; Roberto Orecchia; Mariagiulia Zampino; Nicola Fazio; Marco Venturino; Franco Orsi; Angelica Sonzogni; Ugo Pace; Lorenzo Monfardini
Journal:  World J Surg Oncol       Date:  2007-07-04       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.